Clinical trial
A Phase 2, Open-label, Multicenter Study of MB-105 in Patients With CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL).
NCT06534060 is registered in ClinicalTrials.gov with March Biosciences Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-label, Multicenter Study of MB-105 in Patients With CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL).
- Lead sponsor
- March Biosciences Inc
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 15, 2025
- Completion date
- December 31, 2029
- Enrollment
- 46 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.